I last reviewed Thermo Fisher (TMO) in this February 2, 2024 post. In that post, I concluded that short term demand softness would likely pressure Thermo Fisher's valuation. With the recent release of Q2 and YTD2024 results and minor revisions to the FY2024 outlook, I revisit TMO. Business Overview I reviewed material presented at [...]
I would avoid PPG Industries, Inc. (PPG) and explain why I would do so in my guest post at Dividend Power. Investors relying on a steady stream of dividend income and who focus heavily on various dividend metrics will undoubtedly have a different opinion. Based on my goals, objectives, risk tolerance, and universe of [...]
I can not justify adding to my Moody's (MCO) exposure because of its rich valuation. As a result, I must exercise patience if I want to acquire MCO shares to replace the shares our tax accountants recommended I sell in early June 2024 because of the changes in the taxation of capital gains introduced by [...]
With the recent release of FTV's Q2 and YTD2024 results and FY2024 outlook, I am taking this opportunity to determine if I should increase my Fortive (FTV) exposure. I last reviewed FTV, a Danaher (DHR) spin-off, in this February 1, 2024 post at which time it had just released its Q4 and FY2023 results and [...]
I have expressed my concern in several posts in what appears an element of irrational exuberance. This has made it difficult for me to identify attractively valued companies in which I wish to deploy surplus funds. On occasion, however, a company that appeals to me reaches an attractive or reasonable valuation. Enter Visa (V). I [...]
I last reviewed Lockheed Martin (LMT) in this January 24, 2024 post at which time the most currently available financial information was for Q4 and FY2023. At the time of that post, LMT shares were trading at ~$440 and it was was my 7th largest holdings when I completed my 2023 Year End FFJ [...]
I last reviewed Danaher (DHR) in this February 1, 2024 post at which time the Q4 and FY2023 results had just been released. Prior to this post, I published Danaher Consistently Generates Strong Free Cash Flow and Danaher - Current Weakness Is A Buying Opportunity following the release of Q2 and Q3 results, respectively. In [...]
When I wrote my April 20, 2024 Intuitive Surgical (ISRG) post, shares were trading at ~$366. In that post, I note that it was my 15th largest holding when I completed my 2023 Year End FFJ Portfolio Review at which time shares were trading at ~$337. The appreciation in ISRG's share price coupled with some [...]
I try to identify great companies that, for whatever reason, appear to have temporarily fallen out of favor with investors. When I last added to my Blackstone (BX) exposure on May 9, 2023 @ ~$81.65, I was of the opinion that BX's share price was temporarily depressed for no justifiable reason. In contrast, the share [...]
When I last reviewed BlackRock (BLK) in this April 15 post, the most currently available financial information was for Q1 2024. I considered shares to be reasonably valued and disclosed the purchase of another 30 shares @ ~$770/share on April 12; this increased my BLK exposure to 160 shares in the FFJ Portfolio. In several [...]